- State is the biggest on the East Coast to legalize pot
- Marijuana sales promise to bring new revenue to the state
Voters passed the initiative after Governor
The ballot measure was expected to pass, with 66% of likely voters supporting the initiative in a recent Stockton University poll.
New Jersey will join 11 states that have already fully legalized cannabis, including Maine and Massachusetts. Similar referendums are on Nov. 3 ballots in Arizona, Montana and South Dakota while Mississippi voters will decide whether to allow medical marijuana sales.
Legalizing recreational use may generate $1.9 billion of sales in New Jersey, resulting in nearly $126 million of sales-tax revenue, according to a fiscal estimate from the state’s Office of Legislative Services. Medical marijuana has been legal in New Jersey since 2010.
The push to legalize pot comes as the state plans to borrow as much as $4.5 billion this year to cover budget deficits as the coronavirus pandemic has weakened revenue collections.
Ending the prohibition will also decrease arrests and help boost employment, said
“Instead of spending this money, let’s create more money,” Rudder said. “And instead of arresting people, let’s create jobs.”
New Jersey’s legislature intends to pass enabling legislation by the end of November, according to state Senator
Lawmakers will seek to include smaller business as the industry develops in the state by offering small-scale licenses for entrepreneurs in communities already affected by black-market industries, Scutari said.
“Black marketers are going to be able to compete for licenses as well,” Scutari said. “Some of them may know more about cannabis than anyone else.”
To contact the reporter on this story:
To contact the editors responsible for this story:
William Selway, Michael B. Marois
© 2020 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Tax or Log In to keep reading:
See Breaking News in Context
From research to software to news, find what you need to stay ahead.
Already a subscriber?
Log in to keep reading or access research tools and resources.